Mr. Gurinder Sandhu reports

ADAPTOGENICS HEALTH CORP. ENGAGES IBN TO EXPAND CORPORATE VISIBILITY ACROSS THE INVESTMENT COMMUNITY

Adaptogenics Health Corp. has engaged InvestorBrandNetwork (IBN), a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.

IBN will leverage its investor-focused distribution network, which includes over 5,000 key syndication outlets, various newsletters, social media channels and wire services via InvestorWire, along with blogs and other outreach tools, to generate greater awareness for Adaptogenics. With over 20 years of experience assisting over 500 client partners and a sizable family of 75-plus trusted brands, IBN has amassed a collective audience that includes millions of social media followers. This positions IBN to provide Adaptogenics the solutions needed to reach a wide audience of investors, journalists and the general public.

IBN will be compensated $4,000 (U.S.) per month, for a total of $48,000 (U.S.) for the initial one-year term, after which the agreement will continue on a quarter-to-quarter basis unless terminated. There are no performance factors contained in the engagement, and no securities have been or will be provided to IBN or its principals as compensation for the services. The company confirms that IBN is an arm's-length service provider and that IBN and its principals do not currently have any direct or indirect interest in the securities of the company. IBN's business address is 1108 Lavaca St., suite 110, Austin, Tex., 78701, and it can be reached at 512-354-7000 or Editor@IBN.Ai.

About Adaptogenics Health Corp.

Adaptogenics Health is building a science led company focused on identifying, acquiring, designing, and advancing proprietary peptide and small molecule programs. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The company will continue its existing nutraceutical operations while evaluating GLP-1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.

We seek Safe Harbor.